In this update, we delve into the latest developments with Corbus Pharmaceuticals (CRBP), examining whether the recent hit of our $40 target will lead to a correction to $32-$33 or propel the stock directly towards the 50s. With the 1.618 extension potentially setting a target at $59, we analyze the possibilities and implications for traders and investors.